Southern MS patients with HLA-DRB1*04:05 were less frequently treated with DMD, especially with fingolimod, compared with northern patients (p = 0.018 and 0.009, respectively) (Supplementary Table S5). This evidence concerns the gene HLA-DRB1 and myeloid sarcoma.